MedTrace Logo

Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis

NCT06833749 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2025-02-19

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if KBP-336 works to treat pain in osteoarthritis in individuals living with obesity. It will also learn about the effects on other parameters, such as quality of life and metabolism, as well as safety of KBP-336. The main questions it aims to answer are:

* Does KBP-336 lower knee pain from osteoarthritis in individuals with obesity
* Does KBP-336 lower bodyweight in the same population. Researchers will compare KBP-336 to a placebo (a look-alike substance that contains no drug) to see if KBP-336 works to pain and obesity

Participants will:

* Take KBP-336 or a placebo every week for 6 months
* Visit the clinic once every 2 weeks for checkups and tests
* Keep a diary of their symptoms and the amount of medication they use in addition to KBP-336

Conditions

  • Osteoarthritis in the Knee
  • Obesity

Interventions

DRUG

KBP-336

KBP-336 is a long acting Dual Amylin and Calcitonin Receptor agonist designed for weekly administration through subcutaneous injection.

DRUG

Placebo

Placebo to match KBP-336

Sponsors & Collaborators

  • KeyBioscience AG

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-28
Primary Completion
2026-11-30
Completion
2026-12-31

Countries

  • Czechia
  • Denmark
  • Hong Kong
  • Moldova
  • Poland
  • Romania

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06833749 on ClinicalTrials.gov